{"id":"indacaterol-and-tiotropium","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Indacaterol is a long-acting beta-2 agonist (LABA) that stimulates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and increased cAMP levels. Tiotropium is a long-acting muscarinic antagonist (LAMA) that blocks M3 muscarinic receptors, preventing acetylcholine-induced bronchoconstriction. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours.","oneSentence":"Indacaterol and tiotropium is a fixed-dose combination of a long-acting beta-2 agonist and a long-acting muscarinic antagonist that work synergistically to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:40.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT05506865","phase":"PHASE4","title":"Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2012-09","conditions":"COPD","enrollment":73},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT04011475","phase":"","title":"A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1617},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT02872090","phase":"PHASE4","title":"Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT02039011","phase":"PHASE4","title":"Ultra-long Acting Bronchodilator Therapy in Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-02","conditions":"Asthma","enrollment":14},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT02125734","phase":"PHASE4","title":"Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":88},{"nctId":"NCT01727024","phase":"PHASE4","title":"Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":140},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT01012765","phase":"PHASE3","title":"Effect of Indacaterol on Inspiratory Capacity (IC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":173},{"nctId":"NCT02473237","phase":"PHASE4","title":"Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2013-04","conditions":"COPD","enrollment":40},{"nctId":"NCT01810692","phase":"","title":"Preference Tiotropium Respimat Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT01437748","phase":"PHASE4","title":"Closing Volume Interpretation and Bronchodilators Effect","status":"COMPLETED","sponsor":"University of Milan","startDate":"2011-08","conditions":"Healthy, COPD","enrollment":40},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT01693003","phase":"PHASE4","title":"Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2013-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT01285492","phase":"PHASE3","title":"Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":160},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT00845728","phase":"PHASE3","title":"Exacerbation Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3439},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01294787","phase":"PHASE3","title":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"COPD","enrollment":85},{"nctId":"NCT01498081","phase":"PHASE2","title":"A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03","conditions":"COPD","enrollment":39},{"nctId":"NCT00877383","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1142},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598},{"nctId":"NCT00846586","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1134},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Indacaterol and tiotropium","genericName":"Indacaterol and tiotropium","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indacaterol and tiotropium is a fixed-dose combination of a long-acting beta-2 agonist and a long-acting muscarinic antagonist that work synergistically to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}